原发性肝脏神经内分泌肿瘤的诊治现状

摘要/Abstract

摘要： 原发性肝脏神经内分泌肿瘤(primary hepatic neuroendocrine neoplasms, PHNENs)临床少见,惰性的临床表现以及非典型的影像学特征使其术前诊断较为困难。PHNENs的治疗方案目前尚无定论,多数情况下遵循胃肠胰神经内分泌瘤(neuroendocrine neoplasms, NENs)的治疗共识。随着NENs发病率和检出率的逐年上升,PHNENs的病例数也在增加,相关的临床检查及治疗方案日益受到重视。本文对PHNENs的起源、病理分级、影像学检查及治疗做一综述。

张思琦, 任咪, 徐军明, 张金彦. 原发性肝脏神经内分泌肿瘤的诊治现状[J]. 肝脏, 2022, 27(12): 1344-1347.

参考文献

[1] Song JE, Kim BS, Lee CH. Primary hepatic neuroendocrine tumor: a case report and literature review. World J Clin Cases, 2016, 4: 243-247.
[2] 刘哲,李晓明,蔡守旺,等. 原发性肝脏神经内分泌肿瘤误诊分析. 中华转移性肿瘤杂志,2020, 03(1): 52-56.
[3] Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology, 2020, 76(2): 182-188.
[4] Shah MH, Goldner WS, Benson AB, et al. Neuroendocrine and Adrenal Tumors, Version 2. 2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 2021, 19(7): 839-868.
[5] Xia Y, Zhang L, Wu H, et al. Primary hepatic neuroendocrine tumor with multiple liver metastases: A case report with literature review. J Int Med Res, 2020, 48(6): 300060520932114.
[6] 刘少儒,黄贻培,裴晓珊, 等.肝脏神经内分泌肿瘤35例临床病理分析. 岭南现代临床外科, 2021, 21(02): 157-164+170.
[7] 李小帅,张孟超,曲阳春,等. 肝脏原发性神经内分泌肿瘤影像学诊断与肝动脉化学治疗栓塞术治疗6例分析. 中华肝脏病杂志, 2018, 26(4): 294-297.
[8] Zandee WT, de Herder WW. The Evolution of Neuroendocrine Tumor Treatment Reflected by ENETS Guidelines. Neuroendocrinology, 2018, 106(4): 357-365.
[9] Sadowski SM, Neychev V, Millo C, et al. Prospective study of 68ga-dotatate positron emission tomography/computed tomography for detecting gastro-entero-pancreatic neuroendocrine tumors and unknown primary sites. J Clin Oncol, 2016, 34(6): 588-596.
[10] Strosberg JR, Fine RL, Choi J, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer, 2011, 117(2): 268-275.
[11] 蒋桂星,林天宇,陈炯煌,等. 胆总管神经内分泌肿瘤的诊断与治疗. 中华消化外科杂志, 2019, 18(2): 183-185.
[12] 高志,陈军梅,陈迪,等. TOPK与部分常见恶性肿瘤关系的研究进展. 微循环学杂志, 2019, 29(04): 88-91.
[13] 张皓渝,刘红兵,刘卫华,等. Wnt/β-catenin信号通路在胃癌中的研究进展. 中国现代普通外科进展, 2021, 24(09): 721-724.
[14] Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science, 2011, 331(6021): 1199-1203.
[15] 徐红艳,黄慧,吴艳,等. 儿童肝母细胞瘤临床病理分析. 江西医药, 2021, 56(01): 24-25+30.
[16] Zhang A, Xiang J, Zhang M, et al. Primary hepatic carcinoid tumours: clinical features with an emphasis on carcinoid syndrome and recurrence. J Int Med Res, 2008, 36(4): 848-859.
[17] de Baere T, Elias D, Dromain C, et al. Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year. AJR Am J Roentgenol, 2000, 175: 1619–1625.
[18] Jia Z, Wang W. Yttrium-90 radioembolization for unresectable metastatic neuroendocrine liver tumor: A systematic review. Eur J Radiol, 2018, 100: 23-29.
[19] E Egger ME, Armstrong E, Martin RC 2nd, et al. Transarterial chemoembolization vs radioembolization for neuroendocrine liver metastases: a multi-institutional analysis. J Am Coll Surg, 2020, 230(4): 363-370.
[20] Ramirez RA, Beyer DT, Chauhan A, et al. The role of capecitabine/temozolomide in metastatic neuroendocrine tumors. Oncologist, 2016, 21(6): 671-675.
[21] Welin S, Sorbye H, Sebjornsen S, et al. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer, 2011, 117(20): 4617-4622.
[22] Hadoux J, Malka D, Planchard D, et al. Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma. Endocr Relat Cancer, 2015, 22(3): 289-298.
[23] Girot P, Baudin E, Senellart H, et al. Oxaliplatin and 5-Fluorouracil in advanced well-differentiated digestive neuroendocrine tumors: a multicenter national retrospective study from the french group of endocrine tumors. Neuroendocrinology, 2022, 112(6): 537-546.
[24] Xu J. Current treatments and future potential of surufatinib in neuroendocrine tumors (NETs). Ther Adv Med Oncol, 2021, 13: 17588359211042689.
[25] Lepage C, Dahan L, Bouarioua N, et al. Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours. Dig Liver Dis, 2017, 49(5): 568-571.
[26] Kobayashi N, Wild D, Kaul F, et al. Retrospective study of peptide receptor radionuclide therapy for Japanese patients with advanced neuroendocrine tumors. J Hepatobiliary Pancreat Sci, 2021, 28(9): 727-739.
[27] Lee L, Ito T, Jensen RT. Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence. Expert Opin Pharmacother, 2018, 19(8): 909-928.
[28] 中华医学会消化病学分会胃肠激素与神经内分泌肿瘤学组. 胃肠胰神经内分泌肿瘤诊治专家共识(2020·广州). 中华消化杂志,2021,41(02): 76-87.
[29] Lu M, Zhang P, Zhang Y, et al. Efficacy, Safety, and biomarkers of toripalimab in patients with recurrent or metastatic neuroendocrine neoplasms: a multiple-center phase Ib trial. Clin Cancer Res, 2020, 26(10): 2337-2345.
[30] Moris D, Tsilimigras DI, Ntanasis-Stathopoulos I, et al. Liver transplantation in patients with liver metastases from neuroendocrine tumors: A systematic review. Surgery, 2017, 162(3): 525-536.